Company intelligence / Profile preview

Hsiri Therapeutics

Media, Pennsylvania, United Stateshsiritherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Hsiri Therapeutics is developing novel small molecule antibiotics targeting drug-resistant bacterial and fungal pathogens, with a focus on unmet needs such as TB, NTM diseases, and MDR gram-negative bacteria. The company has established partnerships for R&D but no late-stage clinical results are publicly available.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (antibiotics/antimicrobials)
Industry: Biotech

Partnerships

Shionogi & Co., Ltd. – license agreement and collaborative R&D for TB/NTM therapeuticsU.S. Department of Defense – support for drug discovery effortsNational Institutes of Health – support for drug discovery efforts

Beyond the preview

Go deeper on Hsiri Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hsiri Therapeutics.

Explore the full profile